Xanya Sofra¹* and Sheetal Badami²

¹Department of Research, New School for Social Research, New York, USA
²MBBS, DA, University of Mumbai, Maharashtra, India

*Corresponding Author: Xanya Sofra, Department of Research, New School for Social Research, New York, USA.

Received: May 14, 2021; Published: May 25, 2021

Abstract

  Treating physicians have consistently recommended exercise to either prevent diabetes or de-escalate symptomatology. Diabetic complications, however render physical activity undesirable or unattainable. These involve: hypothyroidism leading to substantial weight gain; perpetual fatigue due to accumulation of white adipose tissue serving as fat storage, and inadequate supply of brown fat to generate energy; accumulated toxicity causing hormonal imbalance that increases hunger; chronic pain and wounds on extremities associated with diabetic neuropathy, etc. Recent research with an effortless exercise method has demonstrated enhanced fitness and T3 increase, juxtaposed by decreased inflammation, an optimal relationship between leptin and ghrelin that control appetite, and a significant decrease of visceral fat along with VLDL, the very low density lipoprotein that carries triglycerides to the tissues. We measured the fasting and postprandial glucose and insulin of 21 diabetics and 20 prediabetics respectively, pre and post twenty treatments. There was a statistically significant decrease in both fasting and postprandial glucose and insulin for all subjects who also exhibited increased skeletal muscle mass, normalized T3 levels, decreased visceral and overall fat, along with reduced CRP, advocating diminished inflammation. Dyslipidaemia appeared to subside as denoted by suppressed levels of triglycerides contrasted by elevated HDL.

Keywords: Diabetes Mellitus; Metabolism; Visceral Fat; Insulin; Cholesterol

References

1. Alberti KGMM and Zimmet PZ. “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation”. Diabetic Medicine7 (1998): 539-553.
2. Canivell S and Gomis R. “Diagnosis and classification of autoimmune diabetes mellitus”. Autoimmunity Reviews4-5 (2014): 403-407.
3. Marchesini G., et al. “WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes”. Diabetic Medicine4 (2004): 383-387.
4. Mazziotti G., et al. “Diabetes in Cushing syndrome: basic and clinical aspects”. Trends in Endocrinology and Metabolism12 (2011): 499-506.
5. Malka D., et al. “Risk factors for diabetes mellitus in chronic pancreatitis”. Gastroenterology5 (2000): 1324-1332.
6. Hannon AM., et al. “Diabetes in patients with acromegaly”. Current Diabetes Reports2 (2017): 8.
7. Finkelstein SM., et al. “Diabetes mellitus associated with cystic fibrosis”. The Journal of Pediatrics3 (1988): 373-377.
8. Mitchell TC and McClain DA. “Diabetes and hemochromatosis”. Current Diabetes Reports5 (2014): 1-10.
9. La Batide-Alanore A., et al. “Diabetes as a marker of pheochromocytoma in hypertensive patients”. Journal of Hypertension9 (2003): 1703-1707.
10. Beliard S., et al. “Atypical neuroleptics and diabetes”. Diabetes and Metabolism3 (2003): 296-299.
11. Gulliford MC., et al. “Risk of diabetes associated with prescribed glucocorticoids in a large population”. Diabetes Care12 (2006): 2728-2729.
12. Spiegel RJ. “Alpha interferons: a clinical overview”. Urology4 (1989): 75-79.
13. Mohn A., et al. “The effect of subclinical hypothyroidism on metabolic control in children and adolescents with Type 1 diabetes mellitus”. Diabetic Medicine1 (2002): 70-73.
14. Giger J., et al. “Activity of the β-myosin heavy chain antisense promoter responds to diabetes and hypothyroidism”. American Journal of Physiology-Heart and Circulatory Physiology6 (2007): H3065-H3071.
15. Díez JJ and Iglesias P. “An analysis of the relative risk for hypothyroidism in patients with Type 2 diabetes”. Diabetic Medicine12 (2012): 1510-1514.
16. Distiller LA., et al. “Type 2 diabetes mellitus and hypothyroidism: the possible influence of metformin therapy”. Diabetic Medicine2 (2014): 172-175.
17. Gavin LA., et al. “The mechanism of impaired T3 production from T4 in diabetes”. Diabetes8 (1981): 694-699.
18. Falzacappa CV., et al. “Thyroid hormone T3 counteracts STZ induced diabetes in mouse”. PloS one5 (2011): e19839.
19. Donath MY and Halban PA. “Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications”. Diabetologia3 (2004): 581-589.
20. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus”. Diabetes Care1 (2003): s5-s20.
21. Verga Falzacappa C., et al. “3, 5, 3′‐triiodothyronine (T3) is a survival factor for pancreatic β‐cells undergoing apoptosis”. Journal of Cellular Physiology2 (2006): 309-321.
22. Verga Falzacappa C., et al. “The TRβ1 is essential in mediating T3 action on Akt pathway in human pancreatic insulinoma cells”. Journal of Cellular Biochemistry5 (2009): 835-848.
23. Ginsberg HN., et al. “Regulation of plasma triglycerides in insulin resistance and diabetes”. Archives of Medical Research3 (2005): 232-240.
24. Liu J., et al. “Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: a 15-year follow-up of the Chinese Multi-provincial Cohort Study”. Diabetes Research and Clinical Practice2 (2012): 217-224.
25. Steinmetz A. “Lipid‐lowering therapy in patients with type 2 diabetes: the case for early intervention”. Diabetes/Metabolism Research And Reviews4 (2008): 286-293.
26. Wiggin TD., et al. “Elevated triglycerides correlate with progression of diabetic neuropathy”. Diabetes7 (2009): 1634-1640.
27. Sofra X and Lampe N. “A Randomized Longitudinal Double-Blind Clinical Trial on Long-Term Neuropathic Symptomatology Relief and Pain Analgesia”. Health07 (2020): 738.
28. Sofra X and Lampe N. “Technological Advances in Accelerated Wound Repair and Regeneration”. Health7 (2020): 717-737.
29. Chattopadhyay M., et al. “Enhanced ROS production and oxidative damage in overall white adipose tissue mitochondria in obese and type 2 diabetes subjects”. Molecular and Cellular Biochemistry 399 (2015): 95-103.
30. Ceriello A. “Acute Hyperglycaemia and Oxidative Stress Generation”. Diabetic MedicineS3 (2004): S45-S49.
31. Vassort G and Turan B. “Protective role of antioxidants in diabetes-induced cardiac dysfunction”. Cardiovascular Toxicology2 (2010): 73-86.
32. Zanuso S., et al. “Exercise for the management of type 2 diabetes: a review of the evidence”. Acta Diabetologica1 (2010): 15-22.
33. Sigal RJ., et al. “Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association”. Diabetes Care6 (2006): 1433-1438.
34. Tuomilehto J., et al. “Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance”. New England Journal of Medicine18 (2001): 1343-1350.
35. Martínez VB and González-Juanatey JR. “Markers of inflammation and cardiovascular disease”. American Journal of Cardiovascular Drugs1 (2009): 3-7.
36. Pearson TA., et al. “Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association”. Circulation3 (2003): 499-511.
37. Doi Y., et al. “Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study”. Diabetes Care10 (2005): 2497-2500.
38. Yasunari K., et al. “Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein”. Hypertension3 (2002): 777-780.
39. Paepegaey AC., et al. “High levels of CRP in morbid obesity: the central role of adipose tissue and lessons for clinical practice before and after bariatric surgery”. Surgery for Obesity and Related Diseases1 (2015): 148-154.
40. Matsuzama Y. “Establishment of a concept of visceral fat syndrome and discovery of adiponectin”. Proceerings of the Japan Academy2 (2010): 131-141.
41. Despres J. “The Insulin Resistance – Dyslipidemic Syndrome Of Visceral Obesity: Effect on Patients’ Risk”. Obesity Research 6 (2012): 8S-17S.
42. Lee CC., et al. “Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis”. Diabetologia6 (2009): 1040-1047.
43. Gillett MJ. “International expert committee report on the role of the A1c assay in the diagnosis of diabetes: diabetes care 7 (2009): 1327-1334.
44. Marín-Peñalver JJ., et al. “Update on the treatment of type 2 diabetes mellitus”. World Journal of Diabetes17 (2016): 354.
45. Peirce NS. “Diabetes and exercise”. British Journal of Sports Medicine3 (1999): 161-172.
46. Israili ZH. “Advances in the treatment of type 2 diabetes mellitus”. American Journal of Therapeutics2 (2011): 117-152.
47. Richter EA., et al. “Diabetes and exercise”. The American Journal of Medicine1 (1981): 201-209.
48. Pedersen BK., et al. “Muscle-Derived Interleukin-6: Possible Biological Effects”. The Journal of Physiology 536 (2001): 329-337.
49. Kjaer M., et al. “Glucoregulation and Hormonal Responses to Maximal Exercise in Non-Insulin-Dependent Diabetes”. Journal of Applied Physiology 68 (1990): 2067-2074.
50. Marliss EB and Vranic M. “Intense Exercise Has Unique Effects on Both Insulin Release and Its Roles in Glucoregulation: Implications for Diabetes”. Diabetes 51 (2002): S271-S283.
51. Bassuk SS and Manson JE. “Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease”. Journal of Applied Physiology (2005).
52. Zinman B and Vranic M. “Diabetes and exercise”. The medical clinics of North America1 (1985): 145-157.
53. Morrato EH., et al. “Are health care professionals advising patients with diabetes or at risk for developing diabetes to exercise more?” Diabetes Care3 (2006): 543-548.
54. Peirce NS. “Diabetes and exercise”. British Journal of Sports Medicine3 (1999): 161-172.
55. American Diabetes Association, 2002. Diabetes mellitus and exercise”. Diabetes Care1 (2002): s64-s64.
56. Sofra X and Lampe N. “Empowering the woman: a comprehensive model of sexual anti-ageing”. Journal of Aesthetic Nursing3 (2020): 118-127.
57. Sofra X. “Gain without pain: beyond sport effortless exercise solutions”. Journal of Aesthetic Nursing5 (2020): 202-210.
58. Sofra X and Badami S. “Adverse Effects of Sedentary Lifestyles: Inflammation, and High-Glucose Induced Oxidative Stress-A Double Blind Randomized Clinical Trial on Diabetic and Prediabetic Patients”. Health08 (2020): 1029.
59. Sofra X. “How to get rid of visceral fat: a randomised double-blind clinical trial”. Journal of Aesthetic Nursing7 (2020): 268-275.
60. Sofra X. “The Importance of Systemic Balance in Safeguarding Health: A Randomized Double-Blind Clinical Trial on VLDL, Triglycerides, Free T3, Leptin, Ghrelin, Cortisol and Visceral Adipose Tissue”. Health08 (2020): 1067.
61. Sofra X. “The Affinity between Obesity and COVID-19”. Journal of Endocrinology and Metabolism2 (2020): 1-13.

Citation

Citation: Xanya Sofra and Sheetal Badami. “Exercise Solutions for the Optimal Metabolic Control of Type 2 Diabetes”. Acta Scientific Gastrointestinal Disorders 4.6 (2021): 54-69.

Copyright

Copyright: © 2021 Xanya Sofra and Sheetal Badami. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.